Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: February 1, 2023

Details for Patent: RE39820

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: RE39820
Title:Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Abstract:Compounds of the formula ##STR00001## of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3.alpha.-(6.beta., 7.beta.-epoxy)-tropanyl methobromide and R.sub.1 is 2-thienyl; (b) A is 3.alpha.-(6, 7dehydro)-tropanyl methobromide and R.sub.1 is 2-thienyl; (c) A is 3.beta.-tropanyl methobromide and R.sub.1 is 2-thienyl; and, (d) A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide and R.sub.1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
Inventor(s): Banholzer; Rolf (Stuttgart, DE), Bauer; Rudolf (Ockenheim, DE), Reichl; Richard (Gau-Algesheim, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:11/254,213
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Dosage form;

Drugs Protected by US Patent RE39820

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE39820

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany39 31 041.8Sep 16, 1989
PCT/EP90/01517Sep 08, 1990
PCT/EP90/01517Sep 8, 1990

International Family Members for US Patent RE39820

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 103914 See Plans and Pricing
Australia 642913 See Plans and Pricing
Australia 6431890 See Plans and Pricing
Bulgaria 61295 See Plans and Pricing
Canada 2066248 See Plans and Pricing
Czech Republic 284589 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.